A Cross-Study Analysis Evaluating the Effects of Food on the Pharmacokinetics of Rivaroxaban in Clinical Studies.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 12, p. 1607, doi. 10.1002/jcph.958
- By:
- Publication type:
- Article
Works matching IS 00912700 AND DT 2017 AND VI 57 AND IP 12
Results: 13
1
2
Pharmacokinetics, Safety, and Tolerability of Glecaprevir and Pibrentasvir in Healthy White, Chinese, and Japanese Adult Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 12, p. 1616, doi. 10.1002/jcph.959
- By:
- Publication type:
- Article
3
Bioequivalence of Intravenous and Oral Rolapitant: Results From a Randomized, Open-Label Pivotal Study.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 12, p. 1600, doi. 10.1002/jcph.966
- By:
- Publication type:
- Article
4
Model-Based Assessment Using Conventional Bioequivalence Limits to Ensure Safety and Efficacy of Rivaroxaban in Patients Undergoing Hip or Knee Replacement.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 12, p. 1591, doi. 10.1002/jcph.930
- By:
- Publication type:
- Article
5
A Dual-Administration Microtracer Technique to Characterize the Absorption, Distribution, Metabolism, and Excretion of [<sup>14</sup>C]Seletalisib (UCB5857) in Healthy Subjects.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 12, p. 1582, doi. 10.1002/jcph.954
- By:
- Publication type:
- Article
6
Population Pharmacokinetic Analysis of Vaginally and Intravenously Administered Oxytocin in Postmenopausal Women.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 12, p. 1573, doi. 10.1002/jcph.961
- By:
- Publication type:
- Article
7
Dosage Optimization of Nemolizumab Using Population Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Modeling and Simulation.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 12, p. 1564, doi. 10.1002/jcph.969
- By:
- Publication type:
- Article
8
Population Pharmacokinetics of Imatinib in Nigerians With Chronic Myeloid Leukemia: Clinical Implications for Dosing and Resistance.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 12, p. 1554, doi. 10.1002/jcph.953
- By:
- Publication type:
- Article
9
Population Pharmacokinetic and Exposure-Response Analysis of Weekly Teriparatide in Osteoporosis Patients.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 12, p. 1545, doi. 10.1002/jcph.949
- By:
- Publication type:
- Article
10
An Exploratory Study in Healthy Male Subjects of the Mechanism of Mirabegron-Induced Cardiovascular Effects.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 12, p. 1534, doi. 10.1002/jcph.952
- By:
- Publication type:
- Article
11
Exposure-Response Analysis of Nivolumab in Patients With Previously Treated or Untreated Advanced Melanoma.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 12, p. 1527, doi. 10.1002/jcph.962
- By:
- Publication type:
- Article
12
Effect of Agomelatine and Fluoxetine on HAM-D Score, Serum Brain-Derived Neurotrophic Factor, and Tumor Necrosis Factor-α Level in Patients With Major Depressive Disorder With Severe Depression.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 12, p. 1519, doi. 10.1002/jcph.963
- By:
- Publication type:
- Article
13
A Pathogenic Mechanism Potentially Operative in Multiple Progressive Diseases and Its Therapeutic Implications.
- Published in:
- Journal of Clinical Pharmacology, 2017, v. 57, n. 12, p. 1507, doi. 10.1002/jcph.997
- By:
- Publication type:
- Article